
Fabiana Perna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4188763/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia. Cancer Treatment and Research, 2022, 183, 225-254.	0.5	6
2	Safety Starts with Selecting the Targets. Molecular Therapy, 2021, 29, 424-425.	8.2	5
3	Intron retention-induced neoantigen load correlates with unfavorable prognosis in multiple myeloma. Oncogene, 2021, 40, 6130-6138.	5.9	21
4	Mapping the High-Risk Multiple Myeloma Cell Surface Proteome Identifies T-Cell Inhibitory Receptors for Immune Targeting. Blood, 2021, 138, 265-265.	1.4	3
5	Safety and efficacy of plerixafor dose escalation for the mobilization of CD34 ⁺ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica, 2018, 103, 770-777.	3.5	47
6	Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nature Medicine, 2017, 23, 242-249.	30.7	179
7	Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles. Cancer Research, 2017, 77, 1927-1941.	0.9	112
8	Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. Cancer Cell, 2017, 32, 506-519.e5.	16.8	240
9	Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape. Nature Reviews Cancer, 2016, 16, 359-372.	28.4	93
10	Self-renewal of CD133hi cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nature Communications, 2016, 7, 10442.	12.8	144
11	Probing the AML Surfaceome for Chimeric Antigen Receptor (CAR) Targets. Blood, 2016, 128, 526-526.	1.4	1
12	Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy. Translational Cancer Research, 2016, 5, S221-S225.	1.0	21
13	Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis. Journal of Clinical Investigation, 2015, 125, 3532-3544.	8.2	120
14	Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nature Biotechnology, 2015, 33, 646-655.	17.5	130
15	Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell, 2015, 28, 415-428.	16.8	641
16	The Polycomb Group Protein L3MBTL1 Represses a SMAD5-Mediated Hematopoietic Transcriptional Program in Human Pluripotent Stem Cells. Stem Cell Reports, 2015, 4, 658-669.	4.8	7
17	Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nature Biotechnology, 2013, 31, 928-933.	17.5	362
18	PRMT4 Blocks Myeloid Differentiation by Assembling a Methyl-RUNX1-Dependent Repressor Complex. Cell Reports, 2013, 5, 1625-1638.	6.4	77

Fabiana Perna

#	Article	IF	CITATIONS
19	ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression. Cancer Cell, 2012, 22, 180-193.	16.8	504
20	MEF Promotes Stemness in the Pathogenesis of Gliomas. Cell Stem Cell, 2012, 11, 836-844.	11.1	37
21	ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition. Haematologica, 2011, 96, 342-343.	3.5	24
22	JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation. Cancer Cell, 2011, 19, 283-294.	16.8	225
23	Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation. Cancer Cell, 2011, 20, 11-24.	16.8	1,105
24	L3MBTL1 Deficiency Directs the Differentiation of Human Embryonic Stem Cells Toward Trophectoderm. Stem Cells and Development, 2011, 20, 1889-1900.	2.1	10
25	The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation. Science, 2011, 333, 765-769.	12.6	200
26	Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature Chemical Biology, 2011, 7, 818-826.	8.0	240
27	Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20qâ~' polycythemia vera. Blood, 2010, 116, 2812-2821.	1.4	51
28	L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 22552-22557.	7.1	76
29	JAK2V617F-Mediated Phosphorylation of PRMT5 Down-Regulates Its Methyltransferase Activity and Promotes Myeloproliferation. Blood, 2010, 116, 794-794.	1.4	0
30	Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era. Frontiers in Immunology, 0, 13, .	4.8	3